Claims
- 1. Device for transdermal administration, comprisingat least one compound having a therapeutic effect against an overactive bladder in a living body which is selected from the group consisting of (R)-tolterodine or the racemate thereof, salts thereof, prodrugs thereof, and metabolites thereof, and a transdermal administration device selected from the group consisting of a reservoir, a matrix, a drug-in-adhesive, a multi-laminate, a polymer-system with no foils, a iontophoretic device, and combinations thereof, an electroporation, an electroosmosis, an electroincorporation and a jet injection device which contains said compound and which has an hourly flux rate of said at least one compound from about 0.1 μg/h/cm2 to about 100 μg/h/cm2.
- 2. Device for transdermal administration according to claim 1, characterized in that tolterodine essentially is in its R-isomeric form.
- 3. Device for transdermal administration according to claim 1, characterized in that tolterodine essentially is in racemic form.
- 4. Device for transdermal administration according to claim 1, characterized in that the (R)-tolterodine is the tolterodine metabolite (R)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamine.
- 5. Device for transdermal administration according to claim 1 characterized in that it has a loading of tolterodine from about 0.1 mg/cm2 to about 5 mg/cm2.
- 6. Device for transdermal administration according to claim 1, characterized in that it has an area of from about 2 cm2 to about 100 cm2.
- 7. Device for transdermal administration according to claim 1, characterized in that it delivers said at least one compound for a predefined period of time.
- 8. Device for transdermal administration, comprisingat least one compound having a therapeutic effect against an overactive bladder in a living body which is selected from the group consisting of (R)-tolterodine or the racemate thereof, salts thereof, prodrugs thereof, and metabolites thereof, wherein said at least one compound is present in a complex with cyclodextrin; and a transdermal administration device selected from the group consisting of a reservoir, a matrix, a drug-in-adhesive, a multi-laminate, a polymer-system with no foils, a iontophoretic device, and combinations thereof, an electroporation, an electroosmosis, an electroincorporation and a jet injection device which contains said compound and which has an hourly flux rate of said at least one compound from about 0.1 μg/h/cm2 to about 100 μg/h/cm2.
- 9. Device according to claim 1, characterized in that it has a release profile being, such that it, when applied on the skin at the appropriate time during day or night, administers tolterodine in such a way that a therapeutically effective systemic level of tolterodine prevails mainly during such periods of time during day and night when an effect against overactive bladder is most desirable.
- 10. Device according to claim 1, characterized in that it further comprises a substance enhancing transdermal penetration.
- 11. Device according to claim 1, characterized in that it further comprises a substance reducing irritant reactions.
- 12. Device according to claim 1, characterized in that it is occlusive.
- 13. Method for achieving an effect against an overactive bladder in a living body which comprises transdermally administering with a transdermal administration device of claim 1 at least one compound selected from the group consisting of (R)-tolterodine or the racemate thereof, salts thereof, prodrugs thereof, and metabolites thereof.
- 14. Method according to claim 13, characterized in that tolterodine essentially is in its R-isomeric form.
- 15. Method according to claim 13, characterized in that tolterodine essentially is in racemic form.
- 16. Method according to claim 13, characterized in that the trandsdermally administered compound comprises the (R)-tolterodine metabolite (R)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamine.
- 17. Method according to claim 13, wherein in the treatment is achieved through systemic effect of the transdermally administered compound.
- 18. Method for achieving an effect against an overactive bladder and/or symptoms associated with this condition in a living body which comprises transdermally administering with a transdermal administration device of claim 1 at least one compound selected from the group consisting of (R)-tolterodine or the racemate thereof, salts thereof, prodrugs thereof, and metabolites thereof.
- 19. Method according to claim 13, characterized in that tolterodine is administered in such a way that a therapeutically effective systemic level of tolterodine prevails mainly during those periods of time during day and night when an effect against overactive bladder is most desirable.
- 20. Method according to claim 13, characterized in that tolterodine is administered in such a way that a less than therapeutically effective systemic level of tolterodine prevails mainly during those periods of time during day and night when an effect against overactive bladder is less desirable.
- 21. Device according to claim 1, further comprising at least one pharmaceutically acceptable carrier.
- 22. Device according to claim 4, further comprising tolterodine.
- 23. Device according to claim 1, characterized in that the device is a drug-in-adhesive or reservoir device.
- 24. Device according to claim 1, characterized in that the device is a combination of a drug-in-adhesive device and a reservoir device.
- 25. Device for transdermal administration according to claim 1, characterized in that it has an hourly flux rate of said at least one compound from about 0.2μg/h/cm2 to about 35 μg/h/cm2.
- 26. Device for transdermal administration according to claim 6, characterized in that it has an area of from about 5 cm2 to about 30 cm2.
- 27. Device for transdermal administration according to claim 7, characterized in that it delivers said at least one compound for 12, 24 or 48 hours.
- 28. Device for transdermal administration according to claim 7, characterized in that it delivers said at least one compound for up to 7 or 14 days.
- 29. Device according to claim 8, characterized in the cyclodextrin is β-cyclodextrin.
- 30. Method according to claim 13, further comprising at least one pharmaceutically acceptable carrier.
- 31. Method according to claim 16, characterized in that the (R)-tolterodine metabolite, (R)-N,N-diisopropyl-3-(2-hydroxy-5-hydroxymethylphenyl)-3-phenylpropanamine, is administered together with tolterodine.
- 32. Method according to claim 13, wherein the transdermal administration is carried out using a drug-in-adhesive or reservoir device.
- 33. Method according to claim 13, wherein the transdermal administration is carried out using a combination of a drug-in-adhesive device and a reservoir device.
- 34. Method according to claim 18 characterized in that said at least compound is administered together with at least one pharmaceutically acceptable carrier.
- 35. Method according to claim 18 further comprising oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transdermal administration of a compound comprising tolterodine, salts thereof, prodrugs thereof and metabolites thereof, and optionally together with pharmaceutically acceptable carrier(s).
- 36. Method according to claim 5, characterized in that said oral, sublingual, buccal, nasal, pulmonary, rectal and/or other transdermal administered compound is administered together with at least one pharmaceutically acceptable carrier.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9802864 |
Aug 1998 |
SE |
|
Parent Case Info
This application is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/SE99/01464 which has an International filing date of Aug. 26, 1999, which designated the United States of America.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/SE99/01464 |
|
WO |
00 |
Publishing Document |
Publishing Date |
Country |
Kind |
WO00/12070 |
3/9/2000 |
WO |
A |
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
5382600 |
Jonsson et al. |
Jan 1995 |
A |
Foreign Referenced Citations (3)
Number |
Date |
Country |
9323025 |
Nov 1993 |
WO |
9803067 |
Jan 1998 |
WO |
9803067 |
Jan 1998 |
WO |
Non-Patent Literature Citations (1)
Entry |
Nilvebrant, L. Tolterodine—A New Bladder Selective Antimuscarinic Agent. Eur. J. Pharmacol. 1977, vol. 327, pp. 195-207. |